Short-term resveratrol supplementation stimulates serum levels of bone-specific alkaline phosphatase in obese non-diabetic men

Journal of Functional Foods

Volumn 6, Issue 1, 2014, Pages 305-310

  Poulsen, Morten Møller ^a   Ornstrup, Marie Juul ^a   Harsløf, Torben ^a   Jessen, Niels ^a   Langdahl, Bente Lomholt ^a   Richelsen, Bjørn ^a   Jørgensen, Jens Otto Lunde ^a   Pedersen, Steen Bønløkke ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bone biomarkers; Bone metabolism; Bone specific alkaline phosphatase; Clinical trial; Resveratrol

Indexed keywords

EID: 84895068481     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2013.10.019     Document Type: Article

References (22)

1. Baur J.A., Ungvari Z., Minor R.K., Le Couteur D.G., de Cabo R. Are sirtuins viable targets for improving health span and life span?. Nature Reviews Drug Discovery 2012, 11:443-461.
2. Boissy P., Andersen T.L., Abdallah B.M., Kassem M., Plesner T., Delaisse J.M. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Research 2005, 65:9943-9952.
3. Chang C., Lee T., Sheu W.H. Anti-atherogenic effects of resveratrol via liver X receptor α-dependent upregulation of ATP-binding cassette transporters A1 and G1 in macrophages. Journal of Functional Foods 2012, 4:727-735.
4. Durbin S.M., Jackson J.R., Ryan M.J., Gigliotti J., Alway S.E., Tou J.C. Resveratrol supplementation preserves long bone mass, microstructure, and strength in hindlimb-suspended old male rats. Journal of Bone and Mineral Metabolism 2013.
5. Glover S.J., Eastell R., McCloskey E.V., Rogers A., Garnero P., Lowery J., et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009, 45:1053-1058.
6. Kopeć A., Pítkowska E., Leszczyńska T., Koronowicz A. Effect of long term administration of resveratrol on lipid concentration in selected organs and liver's histology in rats fed high fructose diet. Journal of Functional Foods 2013, 5:299-305.
7. Kurland E.S., Cosman F., McMahon D.J., Rosen C.J., Lindsay R., Bilezikian J.P. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. Journal of Clinical Endocrinology and Metabolism 2000, 85:3069-3076.
8. Lane N.E., Sanchez S., Genant H.K., Jenkins D.K., Arnaud C.D. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis International 2000, 11:434-442.
9. Liu Z.P., Li W.X., Yu B., Huang J., Sun J., Huo J.S., et al. Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomised rat model. Journal of Medicinal Food 2005, 8:14-19.
10. Mizutani K., Ikeda K., Kawai Y., Yamori Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochemical and Biophysical Research Communications 1998, 253:859-863.
11. Momken I., Stevens L., Bergouignan A., Desplanches D., Rudwill F., Chery I., et al. Resveratrol prevents the wasting disorders of mechanical unloading by acting as a physical exercise mimetic in the rat. FASEB Journal 2011, 25:3646-3660.
12. Olholm J., Paulsen S.K., Cullberg K.B., Richelsen B., Pedersen S.B. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. International Journal of Obesity 2010, 34:1546-1553. Lond.
13. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. Journal of Bone and Mineral Research 2003, 18:9-17.
14. Payne R.B., Little A.J., Williams R.B., Milner J.R. Interpretation of serum calcium in patients with abnormal serum proteins. British Medical Journal 1973, 4:643-646.
15. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metabolism 2008, 8:157-168.
16. Pedersen S.B., Olholm J., Paulsen S.K., Bennetzen M.F., Richelsen B. Low Sirt1 expression, which is upregulated by fasting, in human adipose tissue from obese women. International Journal of Obesity 2008, 32:1250-1255. Lond.
17. Poulsen M.M., Larsen J.O., Hamilton-Dutoit S., Clasen B.F., Jessen N., Paulsen S.K., et al. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutrition Research 2012, 32:701-708.
18. Poulsen M.M., Vestergaard P.F., Clasen B.F., Radko Y., Christensen L.P., Stodkilde-Jorgensen H., et al. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomised, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62:1186-1195.
19. Rubin M.R., Bilezikian J.P. Parathyroid hormone as an anabolic skeletal therapy. Drugs 2005, 65:2481-2498.
20. Su J.L., Yang C.Y., Zhao M., Kuo M.L., Yen M.L. Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. Journal of Biological Chemistry 2007, 282:19385-19398.
21. Urena P., de Vernejoul M.C. Circulating biochemical markers of bone remodeling in uremic patients. Kidney International 1999, 55:2141-2156.
22. Vang O., Ahmad N., Baile C.A., Baur J.A., Brown K., Csiszar A. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011, 6:e19881.